Guardian Pharmacy Services (NYSE:GRDN) Director John Ackerman Sells 1,103,364 Shares of Stock

Guardian Pharmacy Services, Inc. (NYSE:GRDN) Director John Ackerman sold 1,103,364 shares of the stock in a transaction on Friday, March 20th. The stock was sold at an average price of $29.68, for a total transaction of $32,747,843.52. Following the completion of the sale, the director owned 345,123 shares in the company, valued at approximately $10,243,250.64. This trade represents a 76.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Guardian Pharmacy Services Stock Down 2.8%

Shares of GRDN stock opened at $36.52 on Thursday. Guardian Pharmacy Services, Inc. has a 12-month low of $19.17 and a 12-month high of $38.12. The firm has a fifty day moving average of $32.62 and a 200-day moving average of $29.87. The firm has a market capitalization of $2.31 billion, a price-to-earnings ratio of 47.43 and a beta of 0.86.

Guardian Pharmacy Services (NYSE:GRDN) last issued its quarterly earnings data on Wednesday, March 11th. The company reported $0.37 EPS for the quarter, topping the consensus estimate of $0.27 by $0.10. The business had revenue of $397.62 million for the quarter, compared to the consensus estimate of $390.04 million. Guardian Pharmacy Services had a return on equity of 31.64% and a net margin of 3.40%.The company’s revenue was up 17.4% compared to the same quarter last year. Research analysts expect that Guardian Pharmacy Services, Inc. will post 0.87 earnings per share for the current year.

More Guardian Pharmacy Services News

Here are the key news stories impacting Guardian Pharmacy Services this week:

• Neutral Sentiment: Market writeup noting broad insider activity at Guardian Pharmacy Services; useful context but not new filings. TipRanks article
• Negative Sentiment: Director Thomas J. Salentine, Jr. sold 3,570,677 shares at an average $29.68 (≈$106.0M). Filing: SEC filing
• Negative Sentiment: Director William E. Bindley sold 3,570,677 shares at $29.68 (≈$106.0M). Filing: SEC filing
• Negative Sentiment: Director John Ackerman sold 1,103,364 shares at $29.68 (≈$32.7M). Filing: SEC filing
• Negative Sentiment: Director/officer Fred Burke sold 671,432 shares at $29.68 (≈$19.9M). Filing: SEC filing
• Negative Sentiment: Insider Kendall Forbes sold 346,672 shares at $29.68 (≈$10.3M). Filing: SEC filing
• Negative Sentiment: Insider David K. Morris sold 187,855 shares at $29.68 (≈$5.6M). Filing: SEC filing
• Negative Sentiment: Major shareholder Equity Fund L.P. Cardinal sold 275,728 shares at $29.68 (≈$8.2M), a ~44% reduction in its stake. Filing: SEC filing

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Rakuten Investment Management Inc. acquired a new stake in Guardian Pharmacy Services in the 3rd quarter valued at approximately $433,000. Geode Capital Management LLC boosted its position in Guardian Pharmacy Services by 65.9% during the 2nd quarter. Geode Capital Management LLC now owns 336,701 shares of the company’s stock worth $7,177,000 after acquiring an additional 133,715 shares during the last quarter. CSM Advisors LLC boosted its position in Guardian Pharmacy Services by 40.9% during the 3rd quarter. CSM Advisors LLC now owns 135,665 shares of the company’s stock worth $3,559,000 after acquiring an additional 39,360 shares during the last quarter. TimesSquare Capital Management LLC grew its stake in shares of Guardian Pharmacy Services by 5.6% during the 3rd quarter. TimesSquare Capital Management LLC now owns 860,173 shares of the company’s stock worth $22,562,000 after acquiring an additional 45,950 shares in the last quarter. Finally, Aristotle Capital Boston LLC grew its stake in shares of Guardian Pharmacy Services by 58.5% during the 3rd quarter. Aristotle Capital Boston LLC now owns 649,463 shares of the company’s stock worth $17,035,000 after acquiring an additional 239,790 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on GRDN shares. UBS Group reiterated a “buy” rating on shares of Guardian Pharmacy Services in a research report on Thursday, March 12th. Stephens lifted their price target on shares of Guardian Pharmacy Services from $35.00 to $36.00 and gave the company an “overweight” rating in a research note on Wednesday, January 14th. Raymond James Financial reiterated an “outperform” rating and issued a $40.00 price target on shares of Guardian Pharmacy Services in a report on Thursday, March 12th. Weiss Ratings reissued a “hold (c+)” rating on shares of Guardian Pharmacy Services in a research report on Monday, December 29th. Finally, Oppenheimer raised their price objective on shares of Guardian Pharmacy Services from $35.00 to $38.00 and gave the stock an “outperform” rating in a report on Thursday, March 12th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Guardian Pharmacy Services has an average rating of “Buy” and a consensus price target of $38.00.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.